Clinical trials in Padua – page 8

Padua has a strong oncology research presence, with many trials focused on breast cancer, lung cancer, colorectal cancer, ovarian cancer, and melanoma. The studies are largely aimed at testing new treatments, comparing them with current standards, and improving outcomes for advanced or hard-to-treat disease.

• Breast cancer, including hormone receptor-positive, HER2-negative, HER2-positive, and triple-negative disease
• Non-small cell lung cancer and small cell lung cancer, especially advanced or metastatic cases
• Colorectal cancer, gastric cancer, biliary tract cancer, and other solid tumors
• Melanoma, urothelial cancer, prostate cancer, and other difficult-to-treat cancers

Much of the work in Padua centers on finding more effective options for patients whose cancer has returned, spread, or stopped responding to standard care.

A major share of the clinical research landscape involves hematologic malignancies and other blood disorders. Trials in this area are testing new therapies and combinations for both newly diagnosed and relapsed disease.

• Leukemia, including acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myeloid leukemia
• Lymphoma, such as diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma
• Multiple myeloma and related plasma cell disorders
• Anemia, hemophilia, and sickle cell disease

These studies often aim to improve disease control, reduce relapse, and expand treatment choices for patients with limited options.

Cardiovascular disease is another important field in Padua, with research addressing prevention, diagnosis, and treatment of heart and vascular conditions. Several trials also focus on reducing long-term risk in high-risk patients.

• Atherosclerotic cardiovascular disease and coronary artery disease
• Heart failure, including systolic dysfunction and HFpEF
• Myocardial infarction, atrial fibrillation, and venous thromboembolism
• Calcific aortic valve stenosis and related structural heart conditions

The goal is often to lower major cardiovascular events and improve everyday clinical management.

Trials in gastroenterology and hepatology are studying inflammatory, metabolic, and advanced liver conditions. Many are designed to relieve symptoms, slow progression, or test new treatment approaches for chronic digestive disease.

• Crohn’s disease, ulcerative colitis, and coeliac disease
• Primary biliary cholangitis, primary sclerosing cholangitis, and cholestatic pruritus
• Cirrhosis, acute-on-chronic liver failure, and hepatocellular carcinoma
• Pancreatic, esophageal, and other digestive cancers

Research in this area also includes efforts to improve symptom control and quality of life for patients with chronic digestive disorders.

Respiratory medicine is well represented, with studies spanning chronic airway disease, fibrotic lung disease, and lung cancer. The focus is often on better symptom control, slowing progression, and evaluating new therapies.

• Asthma, COPD, and chronic bronchiectasis
• Idiopathic pulmonary fibrosis and other interstitial lung diseases
• Respiratory infections and severe inflammatory lung conditions
• Lung cancer, including early-stage, locally advanced, and metastatic disease

Several trials in Padua also explore whether new treatments can improve breathing, reduce flare-ups, or extend survival.

Clinical trials in neurology cover both degenerative and rare neurological conditions. This research aims to improve symptom control, slow disease worsening, and support better long-term function.

• Parkinson’s disease and related movement disorders
• Amyotrophic lateral sclerosis and multiple system atrophy
• Glioblastoma, glioma, and other brain tumors
• Migraine, multiple sclerosis, and other neurological conditions

The local research environment supports studies of both common neurological disorders and highly specialized rare diseases.

A broad group of trials addresses immune-mediated and autoimmune diseases. These studies often test ways to calm harmful inflammation and improve disease control in chronic conditions.

• Systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis
• Psoriasis, atopic dermatitis, and urticaria
• Vasculitis, angioedema, and other immune disorders
• Inflammatory bowel disease and other chronic inflammatory conditions

Many of these trials are designed to improve day-to-day symptom burden while also reducing longer-term complications.

Kidney and urologic trials in Padua include both chronic disease management and cancer-related studies. Researchers are also investigating transplant-related outcomes and protection of kidney function.

• Chronic kidney disease, end-stage kidney disease, and IgA nephropathy
• Kidney transplant rejection and delayed graft function
• Bladder cancer and urothelial carcinoma
• Renal cell carcinoma and other renal tumors

The overall aim is to improve kidney preservation, transplant success, and treatment options for urinary tract cancers.

Trials in endocrinology and metabolic disease cover both common chronic illnesses and rare inherited disorders. Many studies focus on improving metabolic control, reducing complications, and supporting healthier long-term outcomes.

• Diabetes, obesity, and metabolic dysfunction-associated steatotic liver disease
• Phenylketonuria and other inborn metabolic conditions
• Cushing’s disease and congenital adrenal hyperplasia
• Thyroid and other hormonal disorders

This research often combines symptom improvement with broader efforts to reduce disease-related complications.

Eye disease research includes studies of vision-threatening and chronic ocular conditions across children and adults. The main purpose is to improve treatment options and preserve visual function.

• Myopia in children and adolescents
• Glaucoma and neurotrophic keratopathy
• Age-related macular degeneration and geographic atrophy
• Corneal disorders and other ocular surface conditions

These studies reflect a strong interest in both early intervention and long-term eye care.

The city also supports a wide range of pediatric and rare disease trials. These projects often focus on conditions with limited treatment options and aim to improve survival, function, or symptom control.

• Rare genetic diseases such as Pompe disease, Niemann-Pick disease, and Prader-Willi syndrome
• Muscular dystrophy and other inherited neuromuscular disorders
• Rare pediatric cancers, including neuroblastoma and medulloblastoma
• Congenital and neonatal conditions

Much of this work in Padua is aimed at bringing new treatment possibilities to patients with uncommon and serious illnesses.

Infectious disease research covers both prevention and treatment, including serious hospital-based infections and virus-related illnesses. The emphasis is on better protection, faster recovery, and improved clinical management.

• HIV and hepatitis B
• Respiratory syncytial virus, monkeypox, and herpes zoster prevention
• Sepsis and bacteremia
• Urinary tract and other complicated infections

Several trials are aimed at reducing infection risk in vulnerable groups and improving outcomes in acute care settings.

A smaller but important group of trials looks at surgical and acute care needs. These studies are focused on recovery, wound healing, and safer treatment in urgent or high-risk situations.

• Burns and deep skin defects
• Wound closure and scar reduction
• Urgent surgery in patients needing anticoagulation reversal
• Acute respiratory and critical illness conditions

The research here supports better healing and more effective management of complex acute cases.

With a large number of recruiting studies, Padua stands out as an active clinical research center in Italy. Its network of sites and investigators supports broad participation across many disease areas, from common chronic illness to highly specialized rare conditions.

• 764 currently recruiting trials
• 29 research sites
• 239 investigators
• Extensive coverage across oncology, cardiology, neurology, and rare disease research

The overall profile suggests a diverse and highly active trial environment, with strong momentum across multiple therapeutic fields.